Condition: Sickle Cell Disease · Thalassemia, Beta · Thalassemia Alpha · Sponsor: Cyprus Institute of Neurology and Genetics
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
This description comes directly from the study's public registry record.
Petros Kountouris, PhD · 22392623 · admin@inherentnetwork.org
Always discuss trial participation with your own doctor first.
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| Lucrecia Paím Maternity | Luanda, Angola | Recruiting |
| University of Buenos Aires | Buenos Aires, Argentina | Not Yet Recruiting |
| University Hospitals Leuven | Leuven, Belgium | Not Yet Recruiting |
| Universiti Brunei Darussalam | Brunei, Brunei | Not Yet Recruiting |
| Larnaca General Hospital | Larnaca, Cyprus | Recruiting |
| Limassol General Hospital | Limassol, Cyprus | Recruiting |
| Archbishop Makarios III Hospital | Nicosia, Cyprus | Recruiting |
| Paphos General Hospital | Paphos, Cyprus | Recruiting |
| Centre Hospitalier Monkole | Kinshasa, Democratic Republic of the Congo | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Hippokrateio Hospital of Athens | Athens, Greece | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05799118